Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

497.200
-17.300-3.36%
Volume:1.23M
Turnover:609.66M
Market Cap:118.83B
PE:-257.23
High:507.000
Open:493.600
Low:485.200
Close:514.500
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:2.03
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.933
ROE:2.92%
ROA:0.03%
PB:19.09
PE(LYR):-257.23
PS:48.83

Loading ...

Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 Sirius Copd Study of Skb378/Win378

THOMSON REUTERS
·
Jun 09

A Look At Sichuan Kelun-Biotech Biopharmaceutical’s (SEHK:6990) Valuation After Positive 2026 ASCO Lung Cancer Data

Simply Wall St.
·
Jun 08

Movement Alert|Kelun-Biotech Falls 3.15% in Regular Trading, Chairman Continuous Share Sales Combined with Widening Losses Sustain Selling Pressure

Market Focus
·
Jun 08

Domestic Innovative Drugs Initiate Paradigm Shift in First-Line NSCLC Treatment, Says Orient Securities

Stock News
·
Jun 08

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Down 14.8% After ASCO NSCLC Data Spotlight - Has The Bull Case Changed?

Simply Wall St.
·
Jun 06

Shares of SKB BIO Surge Over 7% on Milestone Breakthrough in OptiTROP-Lung05 Study

Stock News
·
Jun 05

Movement Alert|Kelun-Biotech Rises 3.54% in Regular Trading, Buyback Plan and ASCO Clinical Data Provide Dual Catalysts

Market Focus
·
Jun 05

Movement Alert|Kelun-Biotech Rises 3.08% at Open, Proposed Buyback of Up to 10% H Shares Boosts Sentiment

Market Focus
·
Jun 05

SKB BIO Announces Investment in Structured Deposit Product

Stock News
·
Jun 03

Sichuan Kelun-Biotech Biopharmaceutical Co - Subscribes for Czb Structured Deposit Iii of RMB190 Mln on April 22, 2026

THOMSON REUTERS
·
Jun 03

Movement Alert|Kelun-Biotech Biopharmaceutical Falls 3.17% in Regular Trading, Performance Slowdown and Chairman Stake Reduction Continue to Pressure Shares

Market Focus
·
Jun 03

Kelun-Biotech says SKB500 posts 42.7% response rate in first-in-human solid tumor study at ASCO 2026

Reuters
·
Jun 03

Movement Alert|Kelun-Biotech Biopharmaceutical Falls 6.11% in Regular Trading, Chairman Consecutive Share Sales Compound Performance Concerns

Market Focus
·
Jun 02

Movement Alert|Kelun-Biotech Biopharmaceutical Rises 4.5% in Regular Trading, Named Among June Top Golden Stocks with ASCO Data Catalyzing

Market Focus
·
Jun 01

Stock Track | SKB BIO Soars 5.67% at Market Open on Positive Drug Pipeline Developments and Inclusion in Top Stock Picks

Stock Track
·
Jun 01

June Investment Strategy and Top Ten Stock Picks for Hong Kong Stocks

Stock News
·
Jun 01

Kelun-Biotech says Phase III study shows sac-TMT plus Keytruda extends PFS in first-line PD-L1+ NSCLC

Reuters
·
May 30

Kelun-Biotech says China regulator accepts NDA for lunbotinib in RET fusion-positive NSCLC

Reuters
·
May 30

Stock Track | SKB BIO Plummets 5.02% Intraday as Profit-Taking Hits Following Widening Losses Despite Prior Clinical Data Rally

Stock Track
·
May 28

Movement Alert|Kelun-Biotech Biopharmaceutical Falls 3.21% in Regular Trading, Profit-Taking Triggered by Widening Net Losses Despite Prior Rally on Clinical Data

Market Focus
·
May 28